ABC Heart Fail Cardiomyop 2022; 2(2): 131-132
Long-Term Ventricular Assist Devices: Where are We in Brazil?
Silvia Moreira Ayub-Ferreira
, Bruno Biselli
The use of long-term ventricular assist devices (VADs) as a therapeutic option in patients with advanced heart failure (HF) refractory to drug therapy is well established worldwide. The latest update of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) reported more than 27,000 VAD implants between 2010 and 2019, with approximately 3,000 implants annually in recent years. In addition, 12-month survival rates after implantation reached 82%, with significantly improved quality of life and functional capacity.
The technological development of VADs in the last decade has dramatically changed the type of device used. Between 2010 and 2014, axial-flow devices accounted for most VAD implants. Since 2017, centrifugal-flow VADs with magnetic levitation have had a significant increase in the number of implants, accounting for 75% of implanted devices in 2019.
[…]
Keywords: Cardiogenic Shock; Heart Failure; Heart-Assist Devices
652
